Clinical aspects of the use of Anti-CGRP monoclonal antibodies in the prevention of migraine: a description of a clinical case

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents a brief description and advantages of a new targeted migraine therapy from the class of monoclonal antibodies to migraine pain mediator – calcitonin-gene-related peptide or its receptor (Anti-CGRP(r) mAb). Special attention is paid to the efficacy and tolerability criteria of the Anti-CGRP(r) mAb class. On the example of a clinical case of frequent episodic migraine in a young woman, the problems of choosing preventive therapy, taking into account comorbidity and individual preferences of the patient, are discussed. The presented case illustrates the difficulties that may arise during long-term management of the patient and the possibility of increasing the effectiveness of preventive treatment of migraine when switching from one Anti-CGRP mAb(r) to another drug of this class.

Full Text

Restricted Access

About the authors

V. V. Osipova

University Headache Clinic; Z.P. Solovyev Research and Clinical Center for Neuropsychiatry of the Moscow Healthcare Department

Author for correspondence.
Email: osipova_v@mail.ru
ORCID iD: 0000-0002-1570-5009

Dr. Sci. (Med.)

Russian Federation, Moscow; Moscow

Yu. V. Vorobiev

Sechenov First Moscow State Medical University (Sechenov University)

Email: osipova_v@mail.ru
ORCID iD: 0000-0001-9250-8220
Russian Federation, Moscow

A. R. Artemenko

Sechenov First Moscow State Medical University (Sechenov University); Center for Interdisciplinary Dentistry and Neurology

Email: osipova_v@mail.ru
ORCID iD: 0000-0002-6219-3384
Russian Federation, Moscow; Moscow

K. V. Skorobogatikh

University Headache Clinic

Email: osipova_v@mail.ru
ORCID iD: 0000-0002-1279-9548
Russian Federation, Moscow

References

  1. Ayzenberg I., Katsarava Z., Sborowski A., et al. The prevalence of primary headache disorders in Russia: A countrywide survey. Cephalalgia. 2012;32(5):373–81. doi: 10.1177/0333102412438977.
  2. Global, regional, and national age–sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013 GBD 2013 Mortality and Causes of Death Collaborators. Lancet. 2015;385:117–71. doi: 10.1016/S0140-6736(14)61682-2.
  3. The International Classification of Headache Disorders, 3rd edition (ICHD-3). Cephalalgia. 2018;38(1):1–211. doi: 10.1177/0333102417738202.
  4. Татаринова К.В., Артеменко А.Р. Влияние клинических проявлений мигрени, депрессии и нарушения сна на качество жизни пациентов с мигренью. Нервно-мышечные болезни. 2017;(1):43–53. [Tatarinova K.V., Artemen-ko A.R. Influence of clinical manifestations of migraine, depression and sleep disorders on the quality of life of patients with migraine. Nervno-myshechnye bolezni. 2017;(1):43–53. (In Russ.)]. doi: 10.17650/2222-8721-2017-7-1-43-53.
  5. Филатова Е.Г., Осипова В.В., Табеева Г.Р. и др. Диагностика и лечение мигрени: рекомендации российских экспертов. Неврология, нейропсихиатрия, психосоматика. 2020;12(4):4–14. [Filatova E.G., Osipova V.V., Tabeeva G.R., et al. Diagnostika i lechenie migreni: rekomendatsii rossiiskikh ekspertov. Nevrologiya, neiropsikhiatriya, psikhosomatika. 2020;12(4):4–14. (In Russ.)]. doi: 10.14412/2074-2711-2020-4-4-14.
  6. Филатова Е.Г., Латышева Н.В., Екушева Е.В. и др. Бремя мигрени в реальной клинической практике: клинические и экономические аспекты. Журнал неврологии и психиатрии им. Корсакова. 2019;119(1):31–7. [Filatova E.G., Latysheva N.V., Ekusheva E.V. et al Diagnosis and treatment of migraine: recommendations of Russian experts. Zhurnal nevrologii i psikhiatrii im. Korsakova. 2019;119(1):31–7. (In Russ.)]. Doi.10.17116/jnevro201911901131.
  7. Naprienko M.V., Smekalkina L V., Safonov M.I., et al. The Burden of Migraine in Real Clinical Practice: Clinical and Economic Aspects, Neuroscience and Behavioral Physiology. 2020;50(1):20–6. doi: 10.1007/s11055-019-00862-5.
  8. Азимова Ю.Э., Амелин А.В., Алферова В.В. и др. Клинические рекомендации «Мигрень». Журнал неврологии и психиатрии им. С.С. Корсакова. 2022;122(1 3):4–36. [Azimova Yu.E., Amelin A.V., Alferova V.V. et al. Clinical recommendations «Migraine». Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2022;122(1 3):4–36. (In Russ.)]. doi: 10.17116/jnevro20221220134.
  9. Головачева В.А., Парфенов В.А. Когнитивно-поведенческая терапия в лечении пациентов с мигренью. Неврологический журнал. 2015;3(20):37–43. [Golovacheva V.A., Parfenov V.A. Cognitive behavioral therapy in the treatment of patients with migraine. Nevrologicheskii zhurnal. 2015;3(20):37–43. (In Russ.)]. doi: 10.18821/1560-9545-2015-20-3-37-43.
  10. Steiner T.J., Jensen R., Katsarava Z., et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. J Headache Pain. 2019;20(1):57. doi: 10.1186/s10194-018-0899-2.
  11. Chronicle E.P., Mulleners W.M. Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst Rev. 2016;5:CD003226.
  12. Herd C.P., Tomlinson C.L., Rick C., et al. Botulinum toxins for the prevention of migraine in adults. Cochrane Database Syst Rev. 2018;6(6):CD011616.
  13. Xu X.M., Yang C., Liu Y., et al. Efficacy and feasibility of antidepressants for the prevention of migraine in adults: a meta-analysis. Eur J Neurol. 2017;24(8):1022–31. doi: 10.1111/ene.13320.
  14. Dodick D.W., Turkel C.C., DeGryse R.E., et al.; PREEMPT Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program. Headache. 2010;50(6):921–36. doi: 10.1111/j.1526-4610.2010.01678.x.
  15. Татаринова К.В., Артеменко А.Р. Комбинированное лечение хронической мигрени: ботулинический токсин типа А и венлафаксин. Врач. 2017;10:56–60. [Tatarinova K.V., Artemenko A.R. Combined treatment of chronic migraine: botulinum toxin type A and venlafaxine. Vrach. 2017;10:56–60. (In Russ.)].
  16. Steiner T.J., Joseph R., Hedman C., Rose F.C. Metoprolol in the prophylaxis of migraine: parallel-groups comparison with placebo and dose-ranging follow-up. Headache. 1988;28(1):15–23. doi: 10.1111/j.1365-2524.1988.hed2801015.x
  17. Stovner L.J., Linde M., Gravdahl G.B., et al. A comparative study of candesartan versus propranolol for migraine prophylaxis: A randomised, triple-blind, placebo-controlled, double cross-over study. Cephalalgia. 2014;34(7):523–32. doi: 10.1177/0333102413515348.
  18. Martin V.T., Feoktistov A., Solomon G.D. A rational approach to migraine diagnosis and management in primary care. Ann Med. 2021;53(1):1979–90. doi: 10.1080/07853890.2021.1995626.
  19. Амелин А.В., Соколов А.Ю., Ваганова Ю.С. Пятилетний опыт применения нового класса препаратов для таргетной профилактической терапии мигрени. Российский неврологический журнал. 2021;26(3):4–14. [Amelin A.V., Sokolov A.Yu., Vaganova Yu.S. Five-year experience of using a new class of drugs for targeted prophylactic therapy of migraine. Rossiiskii nevrologicheskii zhurnal. 2021;26(3):4–14. (In Russ.)]. doi: 10.30629/2658-7947-2021-26-3-4-14.
  20. Ailani J., Burch R.C., Robbins M.C. The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice. Headache. 2021;61:1021–39. doi: 10.1111/head.14153
  21. Diener H.C., Forderreuther S., Gaul C., et al. Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor: Addition to the S1 guideline: Therapy of migraine attacks and prevention of migraine. Recommendations of the Germany Society of Neurology and the German Migraine and Headache Society. Neurol Res Pract. 2020;2:11. doi: 10.1186/s42466-020- 00057-1.
  22. Скоробогатых К.В., Табеева Г.Р. Кальцитонин-ген-родственный пептид в патогенезе первичных головных болей. Российский журнал боли. 2010;(1):1–52. [Skorobogatykh K.V., Tabeeva G.R. alcitonin-gene-related peptide in the pathogenesis of primary headaches. Rossiiskii zhurnal boli. 2010;(1):1–52. (In Russ.)].
  23. Schoenen J., Manise M., Nonis R., et al. Monoclonal antibodies blocking CGRP transmission: An update on their added value in migraine prevention. Rev Neurol (Paris). 2020;176(10):788–803. doi: 10.1016/j.neurol.2020.04.027.
  24. Barbanti P., Egeo G., Aurilia C., et al.; FRIEND-Study Group. Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study). J Headache Pain. 2022;23(1):46. doi: 10.1186/s10194-022-01396-x.
  25. Cantarelli L., Pestana Grafina D., Gonzalez Perez A., et al. Efficacy and Safety of Erenumab, Galcanezumab, and Fremanezumab in the Treatment of Drug-Resistant Chronic Migraine: Experience in Real Clinical Practice. Ann Pharmacother. 2022;18:10600280221118402. doi: 10.1177/10600280221118402.
  26. Dodick D.W., Ashina M., Brandes J.L., et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018; 38:1026–37. doi: 10.1177/0333102418759786.
  27. Сергеев А.В., Табеева Г.Р, Филатова Е.Г. и др. Применение новой биологической патогенетической терапии мигрени в клинической практике: консенсус экспертов российского общества по изучению головной боли. Неврология, нейропсихиатрия, психосоматика. 2022;5:109–16. [Sergeev A.V., Tabeeva G.R., Filatova E.G. Application of new biological pathogenetic therapy of migraine in clinical practice: consensus of experts of the Russian Society for the Study of Headache. Nevrologiya, neyropsikhiatriya, psikhosomatika. 2022;5:109–16. (In Russ.)]. doi: 10.14412/2074-2711-2022-5-109-116.
  28. Sacco S., Amin F.M., Ashina M., et al. European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention-2022 update. J Headache Pain. 2022;23(1):67. doi: 10.1186/s10194-022-01431-x.
  29. Eigenbrodt A.K., Ashina H., Khan S., et al. Diagno-sis and management of migraine in ten steps. Nature Reviews Neurology. 2021;17(8):501–14. doi: 10.1038/s41582-021-00509-5.
  30. Gottschalk C., Buse D.C., Marmura M.J. et al. importance of an early onset of migraine prevention: an evidence-based, hypothesis-driven scoping literature review. Ther Adv Neurol Disord. 2022;31;15:17562864221095902. doi: 10.1177/17562864221095902.
  31. Осипова В.В., Филатова Е.Г., Артеменко А.Р. и др. Диагностика и лечение мигрени: рекомендации российских экспертов. Журнал неврологии и психиатрии им. Корсакова. 2017;2:28–42. [Osipova V.V., Filatova E.G., Artemenko A.R. Diagnosis and treatment of migraine: recommendations of Russian experts. Zhurnal nevrologii i psikhiatrii im. Korsakova. 2017;2:28–42. (In Russ.)]. doi: 10.17116/jnevro20171171228-42.
  32. Goadsby P.J., Silberstein S.D., Yeung P.P., et al. Long-term safety, tolerability, and efficacy of fremanezumab in migraine: A randomized study. Neurology. 20203;95(18):e2487-e2499. doi: 10.1212/WNL.0000000000010600.
  33. Ferrari M.D., Zuurbier K.W.M, Barash S., и др. Fremanezumab in individuals with chronic migraine who had inadequate response to onabotulinumtoxinA and topiramate or valproic acid. Headache. 2022;62(4):530–33. doi: 10.1111/head.14294.
  34. Табеева Г.Р., Осипова В.В., Филатова Е.Г. и др. Диагностика и лечение лекарственно-индуцированной головной боли: рекомендации российских экспертов. Неврология, нейропсихиатрия, психосоматика. 2022;14(1):4–13. [Tabeeva G.R., Osipova V.V., Filatova E.G. Diagnosis and treatment of drug-induced headache: recommendations of Russian experts. Nevrologiya, neyropsikhiatriya, psikhosomatika. 2022;14(1):4–13. (In Russ.)]. doi: 10.14412/2074-2711-2022-1-4-13.
  35. Driessen M.T., Cohen J.M., Thompson S.F., et al. Real-world effectiveness after initiating fremanezumab treatment in US patients with episodic and chronic migraine or difficult-to-treat migraine. J Headache Pain. 2022;23(1):56. doi: 10.1186/s10194-022-01415-x.
  36. Iannone L.F., Fattori D., Marangoni M., et al. Switching Onabotulinumtoxin A to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine. CNS Drugs. 2023;37(2):189–202. doi: 10.1007/s40263-022-00983-5.
  37. Murray A.M., Stern J.I., Robertson C.E., et al. Real-World Patient Experience of CGRP-Targeting Therapy for Migraine: a Narrative Review. Curr Pain Headache Rep. 2022;26(10):783–94. doi: 10.1007/s11916-022-01077-z.
  38. Ashina M., Cohen J.M., Galic M., et al. Efficacy and safety of fremanezumab in patients with episodic and chronic migraine with documented inadequate response to 2 to 4 classes of migraine preventive medications over 6 months of treatment in the phase 3b FOCUS study. J Headache Pain. 2021;22(1):68. doi: 10.1186/s10194-021-01279-7.
  39. Осипова В.В. Мигрень в реальной практике: практическое руководство. М.: ГЭОТАР-Медиа, 2023. 120 с. [Osipova V.V. Migraine in real practice: a practical guide. Moscow: GEOTAR-Media, 2023. 120 p. (In Russ.)]. doi: 10.33029/9704-7800-4-MRP-2023-1- 120.
  40. Екушева Е.В., Артеменко А.Р., Ширшова Е.В. и др. Применение Эренумаба у пациентов с хронической мигренью в реальной клинической практике. Российский неврологический журнал. 2021;26(5):44-50. [Ekusheva E.V., Artemen- ko A.R., Shirshova E.V. Erenumab use in patients with chronic migraine in real clinical practice. Rossiyskiy nevrologicheskiy zhurnal. 2021;26(5):44–50. (In Russ.)]. doi: 10.30629/2658-7947-2021-26-5-44-50.
  41. Ващенко Н.В., Ужахов А.М., Богородская М.В. и др. Полугодовое применение CGRP-моноклональных антител в клинической практике: промежуточный анализ эффективности и безопасности. Медицинский совет. 2021;21(1):64–70. [Vashchenko N.V., Uzhakhov A.M., Bogorodskaya M.V. et al. Semi-annual use of CGRP-monoclonal antibodies in clinical practice: an interim analysis of efficacy and safety. Meditsinskiy sovet. 2021;21(1):64–70. (In Russ.)]. doi: 10.21518/2079-701X-2021-21-1-64-70.
  42. Briceno-Casado M.D.P., Gil-Sierra M.D., De-La-Calle-Riaguas B. Switching of monoclonal antibodies against calcitonin gene-related peptide in chronic migraine in clinical practice: a case series. Eur J Hosp Pharm. 2021:ejhpharm-2021-002946. doi: 10.1136/ejhpharm-2021-002946.
  43. Patier Ruiz I., Sanchez-Rubio Ferrandez J., Carcamo Fonfria A., Molina Garcia T. Early Experiences in Switching between Monoclonal Antibodies in Patients with Nonresponsive Migraine in Spain: A Case Series. Eur Neurol. 2022;85(2):132–35. doi: 10.1159/000518899.
  44. Lee M.J., Al-Karagholi M.A., Reuter U. New migraine prophylactic drugs: Current evidence and practical suggestions for non-responders to prior therapy. Cephalalgia. 2023;43(2):3331024221146315. doi: 10.1177/03331024221146315.
  45. Schankin C.J., Broessner G., Gaul C., et al. Response to fremanezumab in migraine patients with and without prior anti-CGRP mAbs – preliminary data from the FINESSE study. Nervenheilkunde 2022;41(05):353. doi: 10.1055/s-0042-1745703.
  46. Buse D.C., Gandhi S.K., Cohen J.M., et al. Improvements across a range of patient-reported domains with fremanezumab treatment: results from a patient survey study. J Headache Pain. 2020;4;21(1):109. doi: 10.1186/s10194-020-01177-4.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. Dynamics of headache frequency in patient Elena X. 45 years old

Download (66KB)
Indexing metadata

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies